טוען...
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms...
שמור ב:
| הוצא לאור ב: | J Clin Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Clinical Oncology
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979134/ https://ncbi.nlm.nih.gov/pubmed/21220597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.3619 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|